A novel splice variant of LOXL2 promotes progression of human papillomavirus-negative head and neck squamous cell carcinoma.
Chao LiuTheresa GuoAkihiro SakaiShuling RenTakahito FukusumiMizuo AndoSayed SadatYuki SaitoJoseph A CalifanoPublished in: Cancer (2019)
The novel LOXL2 variant can promote the progression of HPV-negative HNSCC, in part through FAK/AKT pathway activation, which may provide a new potential therapeutic target among patients with HPV-negative HNSCC.